# US 2024/0197874 A1 · Materials and methods for improving efficacy of adoptive immune cell therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197874 A1
- Document ID: US20240197874A1
- Status: Published application
- Kind: A1
- Application number: 18/287,909
- Filed: 2022-06-01
- Published: 2024-06-20
- Earliest claimed: 2021-06-04
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Joerg J. Goronzy; Cornelia M. Weyand; Jun Jin
- Web page: https://patentgrep.com/patent/US20240197874A1

## CPC

- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4271: {Melanoma antigens}
- A61K 40/46: Viral antigens
- A61P 35/00: Antineoplastic agents
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 5/0636: {T lymphocytes}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/57: Skin; melanoma
- C07K 2319/03: containing a transmembrane segment
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Methods and materials for treating cancer (e.g., melanoma) in a subject and for improving efficacy of adoptive immune cell therapy are described. The methods can include administering immune cells (e.g., chimeric antigen receptor T cells or tumor-infiltrating lymphocytes) having reduced expression of a VPS39 polypeptide to the subject.

## Claims

### Claim 1

A method for treating cancer in a subject, said method comprising administering, to said subject, engineered immune cells, wherein said immune cells have reduced expression of a VPS39 polypeptide.

### Claim 2 (depends on 1)

The method of claim 1, wherein said engineered immune cells are chimeric antigen receptor T cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein said engineered immune cells are tumor infiltrating lymphocytes.

### Claim 4 (depends on 1)

The method of claim 1, wherein said cancer is melanoma.

### Claim 5

A method of increasing efficacy of adoptive cell transfer in a subject, said method comprising administering to the subject chimeric antigen receptor T cells having reduced expression of a VPS39 polypeptide.

### Claim 6 (depends on 5)

The method of claim 5, wherein said subject has cancer.

### Claim 7 (depends on 6)

The method of claim 6, wherein said cancer is melanoma.

### Claim 8

An immune cell comprising an inactivated VPS39 gene.

### Claim 9 (depends on 8)

The immune cell of claim 8, wherein said immune cell is a T cell.

### Claim 10 (depends on 8)

The immune cell of claim 8, wherein said T cell is a chimeric antigen receptor T cell.

### Claim 11 (depends on 8)

The immune cell of claim 8, wherein said immune cell is a tumor-infiltrating lymphocyte.

### Claim 12

An isolated immune cell comprising a disrupted nucleic acid encoding a VPS39 polypeptide, wherein said cell does not express an endogenous VPS39 polypeptide.

### Claim 13 (depends on 12)

The immune cell of claim 12 wherein said immune cell is a T cell.

### Claim 14 (depends on 12)

The immune cell of claim 12, wherein said T cell is a chimeric antigen receptor T cell.

### Claim 15 (depends on 12)

The immune cell of claim 12, wherein said immune cell is a tumor-infiltrating lymphocyte.
